{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:49:21Z","timestamp":1772621361920,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006321","name":"National Institutes of Natural Sciences","doi-asserted-by":"publisher","award":["82172781"],"award-info":[{"award-number":["82172781"]}],"id":[{"id":"10.13039\/501100006321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Portal vein tumor thrombus (PVTT) is a critical factor influencing prognosis and treatment allocation for Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, accurately selecting patients with unresectable HCC and first-order branch PVTT (PVTT1) who would benefit from transarterial chemoembolization (TACE) remains a significant clinical challenge. This study aimed to leverage machine learning to address this issue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a large-scale, retrospective multicenter study utilizing data from 15 tertiary hospitals in China (2012-2021). A Random Survival Forest (RSF) model was constructed to identify key prognostic variables and stratify risk among TACE-treated PVTT1 patients. Model performance was evaluated using the Area Under the Receiver Operating Characteristic Curve (AUC). To mitigate selection bias and confounding factors for survival comparisons, Propensity Score Matching (PSM) was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 3,948 patients enrolled, 763 constituted the TACE-PVTT1 group. The RSF model exhibited robust predictive accuracy for this group, identifying tumor size, tumor number, AST, INR, and age as the top five clinical predictors. Patients in the bottom risk-score tertile were classified as low-risk. Notably, the overall survival (OS) of this low-risk TACE-PVTT1 group was not significantly different from that of the 3,073 TACE-PVTT0 patients (P = 0.19), a finding that was maintained after PSM (P = 0.54). A multivariate Cox analysis confirmed that in this low-risk context, PVTT1 status was not a significant prognostic factor (P = 0.08575). Additionally, TACE conferred a significant survival advantage over sorafenib in patients with PVTT1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The integrated application of RSF and PSM can effectively identify low-risk candidates for TACE among patients with unresectable HCC and PVTT1. Our findings provide strong evidence that for this carefully selected patient subgroup, TACE offers survival outcomes comparable to those for patients without PVTT, highlighting the clinical utility of machine learning in guiding treatment decisions for this challenging disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1766607","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:43:03Z","timestamp":1772602983000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A machine learning approach to identify optimal candidates for transarterial chemoembolization in unresectable HBV-related hepatocellular carcinoma complicated by first-branch portal vein tumor thrombus: a multicenter study"],"prefix":"10.3389","volume":"16","author":[{"given":"Suo","family":"Zhao","sequence":"first","affiliation":[{"name":"The 987 Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army of China","place":["Jibao, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"The 987 Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army of China","place":["Jibao, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Tang","sequence":"additional","affiliation":[{"name":"The 987 Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army of China","place":["Jibao, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Southern Theater Air Force Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, The First Affiliated Hospital of Air Force Medical University","place":["Xi\u2019an, Shaanxi, China"]},{"name":"Department of Breast Cancer Center, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tenghui","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Neurology, Airborne Army Hospital","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huadong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Tangdu Hospital, Air Force Medical University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Western Theater Air Force Hospital","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunzhi","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Southern Theater Air Force Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Southern Theater Air Force Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Southern Theater Air Force Hospital","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[{"name":"The 987 Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army of China","place":["Jibao, Shaanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of hepatocellular carcinoma: A review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-20-854","article-title":"Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a systematic review","volume":"11","author":"Wei","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30178-5","article-title":"Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west","volume":"4","author":"Lu","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B6","first-page":"499","article-title":"Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein","volume":"54","author":"Shuqun","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i40.4527","article-title":"Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus","volume":"24","author":"Peng","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2021.12.004","article-title":"Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review","volume":"21","author":"Tao","year":"2022","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","article-title":"Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)","volume":"9","author":"Zhou","year":"2020","journal-title":"Liver Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.10101058","article-title":"Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival","volume":"258","author":"Chung","year":"2011","journal-title":"Radiology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1321-8","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study","volume":"18","author":"Luo","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1471-230X-13-60","article-title":"Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis","volume":"13","author":"Xue","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000000747","article-title":"Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma","volume":"261","author":"Shim","year":"2015","journal-title":"Ann Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.001593","article-title":"Machine learning in medicine","volume":"132","author":"Deo","year":"2015","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7803","article-title":"Standard errors and confidence intervals for variable importance in random forest regression, classification, and survival","volume":"38","author":"Ishwaran","year":"2019","journal-title":"Stat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318233d835","article-title":"Random survival forests","volume":"6","author":"Taylor","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezy167","article-title":"Statistical primer: propensity score matching and its alternatives","volume":"53","author":"Benedetto","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00534-010-0314-0","article-title":"A new classification for hepatocellular carcinoma with portal vein tumor thrombus","volume":"18","author":"Shi","year":"2011","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-014-0978-3","article-title":"A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"50","author":"Song","year":"2015","journal-title":"J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40644-021-00442-2","article-title":"Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance","volume":"22","author":"Cao","year":"2022","journal-title":"Cancer Imaging"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i13.1330","article-title":"Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization","volume":"27","author":"Chen","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01261-3","article-title":"The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy: a predicted regression model","volume":"40","author":"Lin","year":"2022","journal-title":"Invest New Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2019.01.013","article-title":"Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study","volume":"70","author":"Wang","year":"2019","journal-title":"J Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.024","article-title":"Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study","volume":"175","author":"Fulgenzi","year":"2022","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000004101","article-title":"AFP\/PIVKA-II double-positive status indicates a high-risk subtype of hepatocellular carcinoma in liver transplantation: retrospective cohort study and phosphoproteome evaluation","author":"Xu","year":"2025","journal-title":"Int J Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2582","article-title":"Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death","volume":"31","author":"Cabibbo","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.03.042","article-title":"Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus:a multicenter study","volume":"45","author":"Xiang","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2017.04.016","article-title":"Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis","volume":"19","author":"Silva","year":"2017","journal-title":"HPB (Oxford)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"100552","DOI":"10.1016\/j.aohep.2021.100552","article-title":"Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus","volume":"27","author":"Zhang","year":"2022","journal-title":"Ann Hepatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1109771","article-title":"Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int J Surg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1766607\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:43:04Z","timestamp":1772602984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1766607\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":34,"alternative-id":["10.3389\/fonc.2026.1766607"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1766607","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1766607"}}